Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 11:7:326.
doi: 10.3389/fonc.2017.00326. eCollection 2017.

Efficacy of Complementary Therapies in the Quality of Life of Breast Cancer Survivors

Sahar Zaidi  1 , Showket Hussain  2 , Shalini Verma  1 , Zubia Veqar  1 , Asiya Khan  3 , Sheeraz Un Nazir  2 , Neha Singh  4 , Jamal Ali Moiz  1 , Pranay Tanwar  3 , Anurag Srivastava  3 , G K Rath  3 , Ravi Mehrotra  2
Affiliations
Review

Efficacy of Complementary Therapies in the Quality of Life of Breast Cancer Survivors

Sahar Zaidi et al. Front Oncol. .

Abstract

Breast cancer (BC) is the most common cancer diagnosed in women and the second most common cancer overall, ranking as the fifth cause of death from cancer. The chronicity of the disease produces long-term physiological and psychological manifestations, which adversely affect the quality of life of the individual. The primary treatment while managing cancer presents with various debilitating side effects. With the recent advances in treatment techniques that have improved the survival rate, patients suffer from continuing posttreatment complications. Patients seem to cope well with the stress of treatment of BC and sustain a normal life; however, the deterioration in physical well-being makes the patient functionally inefficient. Exercise has been proven to be an effective, safe, and feasible tool in combating the adverse effects of treatment, prevents complications and decreases the risk of BC-specific mortality. This review briefly presents an overview of the burden of the disease and its management strategies. Owing to the heterogeneity of the population and the multitude of therapies they receive, the response of each patient to treatment is different and so is the magnitude of adverse effects. The review discusses the late sequelae following treatment and evidence supporting the role of physical activity in their management. In conclusion, there is a need for personalized physical activity plans to be developed to suit the individual and their circumstances.

Keywords: aerobic training; breast cancer complications; exercise; quality of life; resistance training.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Role of estrogen in bone homeostasis and musculoskeletal symptoms (OPG, osteoprotegerin; RANK, receptor activator of nuclear kappa-beta; OA, osteoarthritis; SC, spinal cord; BMD, bone mineral density).
Figure 2
Figure 2
Shoulder dysfunction following breast cancer treatment.
Figure 3
Figure 3
Proposed pathways for decline in cardiorespiratory fitness following breast cancer treatment.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2015) 136(5):E359–86.10.1002/ijc.29210 - DOI - PubMed
    1. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg (2010) 34(10):2308–24.10.1007/s00268-010-0683-1 - DOI - PMC - PubMed
    1. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol (2012) 13(11):1141–51.10.1016/S1470-2045(12)70425-4 - DOI - PMC - PubMed
    1. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol (2009) 20(6):993–9.10.1093/annonc/mdn739 - DOI - PubMed
    1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 344(11):783–92.10.1056/NEJM200103153441101 - DOI - PubMed

LinkOut - more resources